GlassScriptPhysician profile
Ewa Anna Susfal
NPI 1073526364
$1,780.33
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,404 · 2020: $376.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $296.33 | 2019-2020 | |
| Amgen INC. | $271.74 | 2019-2020 | |
| Novo Nordisk INC | $209.89 | 2019-2020 | |
| Pfizer INC. | $201.99 | 2019-2020 | |
| Glaxosmithkline, LLC. | $166.45 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $96.13 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.96 | 2019 | |
| Radius Health, INC. | $61.86 | 2019-2020 | |
| Amarin Pharma, INC. | $57.17 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $42.02 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.33 | 2019 | |
| Medtronic Vascular, INC. | $37.65 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.43 | 2019 | |
| Ironwood Pharmaceuticals, INC | $32.72 | 2019-2020 | |
| Abbvie INC. | $32.07 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $31.07 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $26.93 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $22.28 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $12.10 | 2019 | |
| Eisai INC. | $11.30 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.07 | 2019 | |
| Lilly USA, LLC | $10.84 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ewa Susfal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.